Allotopic expression (AE) refers to expression of genes in the cell nucleus that normally are expressed only from the mitochondrial genome. Biomedically engineered AE has been suggested as a possible future tool in gene therapy of certain mitochondria-related diseases, however this view is controversial. While this type of expression has been successfully carried out in yeast, the results in mammals have been conflicting.
Use in Therapy
Gensight Biologics are currently pursuing a clinical program of expressing the ND4 gene in the nucleus to prevent retinal disease.
As of 6th September 2016 and as a result of funds raised at lifespan.io SENS Research Foundation showed ATP6 and ATP8 could be successfully expressed and their published research appears in Nucleic Acid Research  providing proof of concept for the MitoSENS repair approach for repairing age related damage.
- de Grey AD (September 2000). "Mitochondrial gene therapy: an arena for the biomedical use of inteins". Trends Biotechnol. 18 (9): 394–9. doi:10.1016/S0167-7799(00)01476-1. PMID 10942964.
- Oca-Cossio J, Kenyon L, Hao H, Moraes CT (October 2003). "Limitations of allotopic expression of mitochondrial genes in mammalian cells". Genetics. 165 (2): 707–20. PMC . PMID 14573482.
- Perales-Clemente, Ester; et al. (Jan 2011). "Allotopic expression of mitochondrial-encoded genes in mammals: achieved goal, undemonstrated mechanism or impossible task?". Nucleic Acids Res. 39 (1): 225–234. doi:10.1093/nar/gkq769. PMC . PMID 20823090.
- "Gensight". www.gensight-biologics.com. Retrieved 2016-05-20.
- https://www.lifespan.io/campaigns/sens-mitochondrial-repair-project/#updates. Missing or empty